GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluarixBiological: Fluarix-AS50Biological: Fluarix-AS25Biological: Fluarix-AS01EBiological: Fluarix-AS01B
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 425
- Registration Number
- NCT00318149
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
Phase 3
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Tritanrix™- HepBBiological: Hiberix™Biological: Mencevax™ ACW
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 168
- Registration Number
- NCT00317109
- Locations
- 🇿🇦
GSK Investigational Site, Rooihuiskraal, South Africa
Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
Phase 3
Completed
- Conditions
- Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 192
- Registration Number
- NCT00317122
- Locations
- 🇿🇦
GSK Investigational Site, Ga-Rankuwa, South Africa
Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type bDiphtheriaWhole Cell PertussisHepatitis BTetanus
- Interventions
- Biological: Tritanrix-HepB/Meningitec conjugate vaccineBiological: Tritanrix/Hiberix vaccine
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT00317135
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines
Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.
Phase 3
Completed
- Conditions
- Whole Cell PertussisDiphtheriaHaemophilus Influenzae Type bHepatitis BTetanus
- Interventions
- Biological: Tritanrix-HepB/Meningitec conjugate vaccineBiological: Tritanrix/Hiberix vaccine
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT00317187
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type bDiphtheriaTetanusHepatitis BWhole Cell Pertussis
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT00317161
- Locations
- 🇹🇭
GSK Investigational Site, Songkla, Thailand
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
Phase 2
Completed
- Conditions
- Hepatitis BHaemophilus Influenzae Type bTetanusWhole Cell PertussisDiphtheria
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT00317174
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
Completed
- Conditions
- Prostatic Hyperplasia
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 173
- Registration Number
- NCT00316732
- Locations
- 🇬🇧
GSK Investigational Site, Wakefield, United Kingdom
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
Phase 3
Completed
- Conditions
- Cervical Intraepithelial NeoplasiaPapillomavirus Infection
- Interventions
- Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)Biological: Havrix™
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1245
- Registration Number
- NCT00316706
- Locations
- 🇨🇳
GSK Investigational Site, Tao Yuan County, Taiwan
Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
Phase 3
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: ADV groupDrug: LAM group
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2009-10-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT00316719
© Copyright 2025. All Rights Reserved by MedPath